, Lancet, vol.385, pp.2197-2208, 2015.
Multiple myeloma epidemiology and survival: A unique malignancy, Semin. Oncol, vol.43, pp.676-681, 2016. ,
International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma, Lancet Oncol, vol.15, pp.538-548, 2014. ,
Continued improvement in survival in multiple myeloma (MM) including high-risk patients, J. Clin. Oncol, vol.37, 2019. ,
Outcome and survival of myeloma patients diagnosed 2008-2015. Real-world data on 4904 patients from the Swedish Myeloma Registry, vol.103, pp.506-513, 2017. ,
Current Treatment Strategies for Multiple Myeloma, JCO Oncol. Pr, vol.16, pp.5-14, 2020. ,
Immuno-PET for Clinical Theranostic Approaches, Int. J. Mol. Sci, vol.18, 2016. ,
URL : https://hal.archives-ouvertes.fr/in2p3-01951323
Critical Reflection for Nursing and the Helping Professions: A User's Guide ,
, , 2001.
, Immunotherapy in Multiple Myeloma. Front. Immunol, vol.10, 1945.
Monoclonal antibody therapy in multiple myeloma, Leukemia, vol.31, pp.1039-1047, 2017. ,
URL : https://hal.archives-ouvertes.fr/hal-01795709
Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma, N. Engl. J. Med, vol.378, pp.518-528, 2018. ,
Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): A randomised, open-label, phase 3 study, Lancet, vol.394, pp.29-38, 2019. ,
Lenalidomide, and Dexamethasone for Multiple Myeloma, New Engl. J. Med, vol.375, pp.1319-1331, 2016. ,
Bortezomib, and Dexamethasone for Multiple Myeloma, N. Engl. J. Med, vol.375, pp.754-766, 2016. ,
The future of myeloma immunotherapy, Expert Rev. Hematol, vol.11, pp.423-435, 2018. ,
Monoclonal antibodies in the treatment of multiple myeloma: Current status and future perspectives, Leukemia, vol.30, pp.526-535, 2015. ,
Daratumumab for the Treatment of Multiple Myeloma, Front. Immunol, vol.9, issue.9, 2018. ,
, Immunotherapy. Ann. Pharmacother, vol.50, pp.555-568, 2016.
CD38 antibodies in multiple myeloma: Back to the future, Blood, vol.131, pp.13-29, 2018. ,
Pharmacodynamics and Physiologically-Based Pharmacokinetic Modelling of Monoclonal Antibodies, Clin. Pharm, vol.52, pp.83-124, 2013. ,
, Clinical Pharmacokinetics of Therapeutic Monoclonal Antibodies, vol.49, pp.493-507, 2010.
Model-Based Characterization of the Pharmacokinetics of Pembrolizumab: A Humanized Anti-PD-1 Monoclonal Antibody in Advanced Solid Tumors, CPT Pharmacomet. Syst. Pharmacol, vol.6, pp.49-57, 2016. ,
Model-Based Population Pharmacokinetic Analysis of Nivolumab in Patients With Solid Tumors, CPT Pharmacomet. Syst. Pharmacol, vol.6, pp.58-66, 2016. ,
Dose Rationalization of Pembrolizumab and Nivolumab Using Pharmacokinetic Modeling and Simulation and Cost Analysis, Clin. Pharmacol. Ther, vol.103, pp.582-590, 2017. ,
Pharmacokinetics of Daratumumab Following Intravenous Infusion in Relapsed or Refractory Multiple Myeloma After Prior Proteasome Inhibitor and Immunomodulatory Drug Treatment, Clin. Pharm, vol.56, pp.915-924, 2017. ,
Clinical Implications of Complex Pharmacokinetics for Daratumumab Dose Regimen in Patients With Relapsed/Refractory Multiple Myeloma, Clin. Pharmacol. Ther, vol.101, pp.721-724, 2017. ,
CD38 Antibodies in Multiple Myeloma: Mechanisms of Action and Modes of Resistance, Front. Immunol, vol.9, issue.9, 2018. ,
Biological Background of Resistance to Current Standards of Care in Multiple Myeloma, Cells, vol.8, 1432. ,
Promises and Pitfalls in the Use of PD-1/PD-L1 Inhibitors in Multiple Myeloma, Front. Immunol, vol.9, p.2749, 2018. ,
Targeting the PD-1/PD-L1 axis in multiple myeloma: A dream or a reality? Blood, vol.129, pp.275-279, 2017. ,
Marrow stromal cells induce B7-H1 expression on myeloma cells, generating aggressive characteristics in multiple myeloma, Leukemia, vol.27, pp.464-472, 2012. ,
Update on PD-1/PD-L1 Inhibitors in Multiple Myeloma, Front. Immunol, vol.9, p.2431, 2018. ,
, Checkpoint Inhibition in Myeloma: Opportunities and Challenges. Front. Immunol, vol.9, 2018.
Aires-Mejía, I.; et al. PD-L1/PD-1 presence in the tumor microenvironment and activity of PD-1 blockade in multiple myeloma, Leukemia, vol.29, pp.2110-2113, 2015. ,
Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib Study, J. Clin. Oncol, vol.34, pp.2698-2704, 2016. ,
Phase 1b trial of pembrolizumab monotherapy for relapsed/refractory multiple myeloma: KEYNOTE-013, Br. J. Haematol, vol.186, pp.41-44, 2019. ,
Pembrolizumab combined with lenalidomide and low-dose dexamethasone for relapsed or refractory multiple myeloma: Phase I KEYNOTE -023 study, Br. J. Haematol, vol.186, pp.117-121, 2019. ,
Pembrolizumab plus lenalidomide and dexamethasone for patients with treatment-naive multiple myeloma (KEYNOTE-185): A randomised, open-label, phase 3 trial, Lancet Haematol, vol.6, pp.448-458, 2019. ,
Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): A randomised, open-label, phase 3 trial, Lancet Haematol, vol.6, pp.459-469, 2019. ,
The future of checkpoint inhibition in multiple myeloma?, Lancet Haematol, vol.6, pp.439-440, 2019. ,
T cells in multiple myeloma display features of exhaustion and senescence at the tumor site, J. Hematol. Oncol, vol.9, p.116, 2016. ,
Neoantigens in cancer immunotherapy, Science, vol.348, pp.69-74, 2015. ,
Clinical and biological characteristics of myeloma patients influence response to elotuzumab combination therapy, J. Cancer Res. Clin. Oncol, vol.145, pp.561-571, 2018. ,
Randomized phase 2 study: Elotuzumab plus bortezomib/dexamethasone vs bortezomib/dexamethasone for relapsed/refractory MM, Blood, vol.127, pp.2833-2840, 2016. ,
CD38 expression and complement inhibitors affect response and resistance to daratumumab therapy in myeloma, Blood, vol.128, pp.959-970, 2016. ,
Daratumumab resistance is frequent in advanced-stage multiple myeloma patients irrespective of CD38 expression and is related to dismal prognosis, Eur. J. Haematol, vol.100, pp.494-501, 2018. ,
CD38 Expression Levels on Myeloma Cells and the Frequency of Circulating CD38-Positive Treg Cells Are Associated with the Response to Daratumumab in Multiple Myeloma, Blood, vol.132, 1883. ,
, Immune Mediated Mechanisms of Resistance to Daratumumab, vol.132, 2018.
Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy, Nat. Rev. Cancer, vol.16, pp.275-287, 2016. ,
Target-Mediated Drug Disposition of Daratumumab Following Intravenous Infusion in Relapsed or Refractory Multiple Myeloma after Prior Proteasome Inhibitors and Immunomodulatory Drugs: A Population Pharmacokinetic Analysis, Blood, vol.126, 2015. ,
Clinical Pharmacokinetics and Pharmacodynamics of Immune Checkpoint Inhibitors, Clin. Pharm, vol.58, pp.835-857, 2019. ,
URL : https://hal.archives-ouvertes.fr/hal-02513473
Monoclonal antibodies: What are the pharmacokinetic and pharmacodynamic considerations for drug development?, Expert Opin. Drug Metab. Toxicol, vol.8, pp.141-160, 2012. ,
Comparative clinical pharmacokinetics of antibody-drug conjugates in first-in-human Phase 1 studies, vol.6, pp.859-870, 2014. ,
Tumor Drug Penetration Measurements Could Be the Neglected Piece of the Personalized Cancer Treatment Puzzle, Clin. Pharmacol. Ther, vol.106, pp.148-163, 2018. ,
The Long Neglected Player: Modeling Tumor Uptake to Guide Optimal Dosing, Clin. Cancer Res, vol.24, pp.3236-3238, 2018. ,
Spatial genomic heterogeneity in multiple myeloma revealed by multi-region sequencing, Nat. Commun, vol.8, p.268, 2017. ,
The Impact of Tumor Heterogeneity on Diagnostics and Novel Therapeutic Strategies in Multiple Myeloma, Int. J. Mol. Sci, 1248. ,
Pharmacokinetics and Exposure-Response Analyses of Daratumumab in Combination Therapy Regimens for Patients with Multiple Myeloma, Adv. Ther, vol.35, pp.1859-1872, 2018. ,
Generation and Characterization of Microvesicles after Daratumumab Interaction with Myeloma Cells, Blood, vol.126, p.1849, 2015. ,
Monocytes and Granulocytes Reduce CD38 Expression Levels on Myeloma Cells in Patients Treated with Daratumumab, Clin. Cancer Res, vol.23, pp.7498-7511, 2017. ,
A phase 1, multicenter, open-label, dose escalation study of elotuzumab in patients with advanced multiple myeloma, Blood, vol.120, pp.552-559, 2012. ,
Monoclonal antibody dose determination and biodistribution into solid tumors, Ther. Deliv, vol.2, pp.333-344, 2011. ,
Individualized Dosing of Therapeutic Monoclonal Antibodies-A Changing Treatment Paradigm?, AAPS J, vol.20, p.99, 2018. ,
Understanding Inter-Individual Variability in Monoclonal Antibody Disposition, vol.8, 2019. ,
Immunotherapy Combinations in Multiple Myeloma-Known Unknowns, N. Engl. J. Med, vol.379, pp.1791-1795, 2018. ,
Approaches to modernize the combination drug development paradigm, Genome Med, 2016. ,
The cost of cancer in Europe, Eur. J. Cancer, vol.129, pp.41-49, 2018. ,
To all involved-we have a problem, Nat. Rev. Clin. Oncol, vol.15, 2018. ,
Dealing with the spiralling price of medicines: Issues and solutions, Intern. Med. J, vol.48, pp.16-24, 2018. ,
Assessment of Overall Survival, Quality of Life, and Safety Benefits Associated With New Cancer Medicines, JAMA Oncol, vol.3, 2017. ,
Theranostic Outcomes in Clinical Practice of Oncology: What, So What, Now What? What's More, Cancer Biother. Radiopharm, vol.34, pp.135-140, 2019. ,
Challenges and shifting paradigms in clinical trials in oncology: The case for immunological and targeted therapies, vol.13, 2019. ,
End points and statistical considerations in immuno-oncology trials: Impact on multiple myeloma, Future Oncol, vol.13, pp.1181-1193, 2017. ,
The beginning of the end for conventional RECIST-novel therapies require novel imaging approaches, Nat. Rev. Clin. Oncol, vol.16, pp.442-458, 2019. ,
Monitoring immune-checkpoint blockade: Response evaluation and biomarker development, Nat. Rev. Clin. Oncol, vol.14, pp.655-668, 2017. ,
Minimal Residual Disease Assessment Within the Bone Marrow of Multiple Myeloma: A Review of Caveats, Clinical Significance and Future Perspectives. Front. Oncol, vol.9, p.699, 2019. ,
MRD in multiple myeloma: More questions than answers?, Blood Cancer J, vol.7, p.639, 2017. ,
International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma, Lancet Oncol, vol.17, pp.328-346, 2016. ,
Immuno-PET: A Navigator in Monoclonal Antibody Development and Applications, Oncology, vol.12, pp.1379-1389, 2007. ,
Overcoming multiple myeloma drug resistance in the era of cancer 'omics, vol.59, pp.542-561, 2017. ,
ImmunoPET to help stratify patients for targeted therapies and to improve drug development, Eur. J. Nucl. Med. Mol. Imaging, vol.43, pp.2166-2168, 2016. ,
URL : https://hal.archives-ouvertes.fr/inserm-01809742
ImmunoPET: Concept, Design, and Applications, Chem. Rev, vol.120, pp.3787-3851, 2020. ,
89Zr-ImmunoPET companion diagnostics and their impact in clinical drug development, J. Label. Compd. Radiopharm, vol.61, pp.727-738, 2018. ,
Preclinical Development of CD38-Targeted [89Zr]Zr-DFO-Daratumumab for Imaging Multiple Myeloma, J. Nucl. Med, vol.59, pp.216-222, 2017. ,
Copper 64-labeled daratumumab as a PET/CT imaging tracer for multiple myeloma, Blood, vol.131, pp.741-745, 2018. ,
Preclinical development and First-in-human imaging of 89Zr-Daratumumab for CD38 targeted imaging of myeloma, J. Nucl. Med, p.203, 2019. ,
Functional Imaging Methods for Assessment of Minimal Residual Disease in Multiple Myeloma: Current Status and Novel ImmunoPET Based Methods, Semin. Hematol, vol.55, pp.22-32, 2018. ,
CD38-targeted Immuno-PET of Multiple Myeloma: From Xenograft Models to First-in-Human Imaging, Radiology, vol.295, pp.606-615, 2020. ,
Exploring Tumor Heterogeneity Using PET Imaging: The Big Picture, Cancers, vol.11, p.1282, 2019. ,
URL : https://hal.archives-ouvertes.fr/inserm-02318425
atezolizumab imaging as a non-invasive approach to assess clinical response to PD-L1 blockade in cancer, Nat. Med, vol.24, pp.1852-1858, 2018. ,
Whole body PD-1 and PD-L1 positron emission tomography in patients with non-small-cell lung cancer, Nat. Commun, vol.9, p.4664, 2018. ,
Biodistribution of 89Zr-trastuzumab and PET Imaging of HER2-Positive Lesions in Patients With Metastatic Breast Cancer, Clin. Pharmacol. Ther, vol.87, pp.586-592, 2010. ,
Tumour targeting and radiation dose of radioimmunotherapy with (90)Y-rituximab in CD20+ B-cell lymphoma as predicted by (89)Zr-rituximab immuno-PET: Impact of preloading with unlabelled rituximab, Eur. J. Nucl. Med. Mol. Imaging, vol.42, pp.1304-1314, 2015. ,
Immuno-PET Imaging to Assess Target Engagement: Experience from 89Zr-Anti-HER3 mAb (GSK2849330) in Patients with Solid Tumors, J. Nucl. Med, vol.60, pp.902-909, 2019. ,
What is the Best Radionuclide for Immuno-PET of Multiple Myeloma? A Comparison Study Between 89Zr-and 64Cu-Labeled Anti-CD138 in a Preclinical Syngeneic Model, Int. J. Mol. Sci, 2019. ,
URL : https://hal.archives-ouvertes.fr/hal-02141555
Fc-Mediated Anomalous Biodistribution of Therapeutic Antibodies in Immunodeficient Mouse Models, Cancer Res, vol.78, pp.1820-1832, 2018. ,
A review of current murine models of multiple myeloma used to assess the efficacy of therapeutic agents on tumour growth and bone disease, vol.77, pp.57-68, 2015. ,
Syndecan-1: A dynamic regulator of the myeloma microenvironment, Clin. Exp. Metastasis, vol.25, pp.149-159, 2007. ,
Role of 18F-FDG PET/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: A consensus statement by the International Myeloma Working Group, Lancet Oncol, vol.18, pp.206-217, 2017. ,
Whither radioimmunotherapy: To be or not to be? Cancer Res, vol.77, pp.2191-2196, 2017. ,
Biodistribution, radiation dosimetry and scouting of 90Y-ibritumomab tiuxetan therapy in patients with relapsed B-cell non-Hodgkin's lymphoma using 89Zr-ibritumomab tiuxetan and PET, Eur. J. Nucl. Med. Mol. Imaging, vol.39, pp.512-520, 2012. ,
Phase III Trial of Consolidation Therapy With Yttrium-90-Ibritumomab Tiuxetan Compared With No Additional Therapy After First Remission in Advanced Follicular Lymphoma, J. Clin. Oncol, vol.26, pp.5156-5164, 2008. ,
Treatment With Ibritumomab Tiuxetan Radioimmunotherapy in Patients With Rituximab-Refractory Follicular Non-Hodgkin's Lymphoma, J. Clin. Oncol, vol.20, pp.3262-3269, 2002. ,
Radioinmunoterapia en el linfoma no Hodgkin, posicionamiento ,
, Experiencia y seguimiento a los 10 años, Revista Española de Medicina Nuclear e Imagen Molecular, vol.36, pp.13-19, 2017.
90Yttrium-Ibritumomab-Tiuxetan as First-Line Treatment for Follicular Lymphoma: 30 Months of Follow-Up Data From an International Multicenter Phase II Clinical Trial, J. Clin. Oncol, vol.31, pp.308-313, 2013. ,
Radioimmunotherapy of lymphoma: An underestimated therapy option, Lancet Haematol, vol.4, pp.6-7, 2017. ,
A Treatment Approach Ahead of Its Time or Past Its Sell-By Date?, J. Clin. Oncol, vol.28, pp.2944-2946, 2010. ,
Cancer Therapy with Alpha-Emitters Labeled Peptides, Semin. Nucl. Med, vol.40, pp.204-208, 2010. ,
Single-Dose Anti-CD138 Radioimmunotherapy: Bismuth-213 is More Efficient than Lutetium-177 for Treatment of Multiple Myeloma in a Preclinical Model ,
URL : https://hal.archives-ouvertes.fr/inserm-01817464
Efficacy of Astatine-211 Radioimmunotherapy of Multiple Myeloma Using an Anti-mCD138 Monoclonal Antibody in a Syngeneic Murine Model, Eur. J. Nucl. Med. Mol. Imaging, vol.45, pp.166-167, 2018. ,
URL : https://hal.archives-ouvertes.fr/inserm-02341491
Comparative analysis of multiple myeloma treatment by CD138 antigen targeting with bismuth-213 and Melphalan chemotherapy, Nucl. Med. Boil, vol.41, pp.30-35, 2014. ,
,
, Monoclonal Antibody in a Murine Model of Multiple Myeloma, J. Nucl. Med, vol.54, pp.1597-1604, 2013.
Comparison of Immuno-PET of CD138 and PET imaging with 64CuCl2 and 18F-FDG in a preclinical syngeneic model of multiple myeloma, Oncotarget, vol.9, pp.9061-9072, 2018. ,
URL : https://hal.archives-ouvertes.fr/hal-01677118